期刊
BMC MEDICINE
卷 13, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s12916-015-0328-1
关键词
Ageing; Antihypertensives; Frailty; Hypertension
资金
- Dunhill Medical Trust [R287/0213]
- Birmingham Science City Translational Medicine Clinical Research and Infrastructure Trials Platform
- Advantage West Midlands
- British Heart Foundation
- Institute de Recherches Internationales Servier
- Imperial College London
- National Institute for Health Research [PDF-2012-05-197] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [PDF-2012-05-197] Funding Source: National Institutes of Health Research (NIHR)
Background: Treatment for hypertension with antihypertensive medication has been shown to reduce stroke, cardiovascular events, and mortality in older adults, but there is concern that such treatment may not be appropriate in frailer older adults. To investigate whether there is an interaction between effect of treatment for hypertension and frailty in older adults, we calculated the frailty index (FI) for all available participants from the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over, and obtained frailty adjusted estimates of the effect of treatment with antihypertensive medication on risk of stroke, cardiovascular events, and mortality. Methods: Participants in HYVET were randomised 1: 1 to active treatment with indapamide sustained release 1.5 mg +/- perindopril 2 to 4 mg or to matching placebo. Data relating to blood pressure, comorbidities, cognitive function, depression, and quality of life were collected at entry into the study and at subsequent follow-up visits. The FI was calculated at entry, based on 60 potential deficits. The distribution of FI was similar to that seen in population studies of adults aged 80 years and above (median FI, 0.17; IQR, 0.11-0.24). Cox regression was used to assess the impact of FI at entry to the study on subsequent risk of stroke, total mortality, and cardiovascular events. Models were stratified by region of recruitment and adjusted for sex and age at entry. Extending these models to include a term for a possible interaction between treatment for hypertension and FI provided a formula for the treatment effect as a function of FI. For all three models, the point estimates of the hazard ratios for the treatment effect decreased as FI increased, although to varying degrees and with varying certainty. Results: We found no evidence of an interaction between effect of treatment for hypertension and frailty as measured by the FI. Both the frailer and the fitter older adults with hypertension appeared to gain from treatment. Conclusions: Further work to examine whether antihypertensive treatment modifies frailty as measured by the FI should be explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据